Author: DOKI, Tomoyoshi; TAKANO, Tomomi; HOHDATSU, Tsutomu
Title: Development of a mouse-feline chimeric antibody against feline tumor necrosis factor-alpha Document date: 2016_6_4
ID: y0x0quha_4
Snippet: In humans, infliximab is used as a therapeutic drug for rheumatoid arthritis (RA). In addition to neutralizing human TNF-alpha, which is a factor aggravating the pathology of RA, infliximab directly injures TNF-alpha-producing cells expressing TNF-alpha on the cell surface through antibodydependent cellular cytotoxicity and complement-dependent cytotoxicity. Infliximab exhibits its treatment effect against RA through these actions. Infliximab is .....
Document: In humans, infliximab is used as a therapeutic drug for rheumatoid arthritis (RA). In addition to neutralizing human TNF-alpha, which is a factor aggravating the pathology of RA, infliximab directly injures TNF-alpha-producing cells expressing TNF-alpha on the cell surface through antibodydependent cellular cytotoxicity and complement-dependent cytotoxicity. Infliximab exhibits its treatment effect against RA through these actions. Infliximab is repeatedly administered at 4-or 8-week intervals until RA remission is observed. Accordingly, to reduce antigenicity for humans, infliximab is expressed in mammalian cells as a mouse-human chimeric antibody prepared by fusing the variable region of mouse mAb and the constant region of human antibody [20] . Human anti-mouse antibody response to the mouse-human chimeric mAb was reduced compared to that of the mouse mAb response, and the adverse reactions after administration were also reduced. Based on these findings, it was hypothesized that the feline anti-mouse antibody response and the development of adverse reactions after administration may be reduced by substituting the amino acid sequence of the feline antibody constant region for that of the mAb 2-4 constant region.
Search related documents:
Co phrase search for related documents- amino acid and cell surface: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- amino acid and chimeric antibody: 1
- amino acid and constant region: 1, 2, 3, 4
- amino acid and finding base: 1
- amino acid and human antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- amino acid and human antigenicity: 1, 2
- amino acid and mammalian cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- amino acid and mouse human: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52
- amino acid and RA rheumatoid arthritis: 1, 2
- amino acid and rheumatoid arthritis: 1, 2, 3, 4, 5, 6
- amino acid and therapeutic drug: 1, 2, 3, 4, 5, 6, 7, 8, 9
- amino acid and tnf alpha: 1, 2, 3, 4
- amino acid and treatment effect: 1, 2, 3, 4, 5, 6, 7, 8
- amino acid and variable region: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
- amino acid sequence and mammalian cell: 1, 2
- amino acid sequence and mouse human: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- amino acid sequence and rheumatoid arthritis: 1
- amino acid sequence and therapeutic drug: 1
- amino acid sequence and tnf alpha: 1
Co phrase search for related documents, hyperlinks ordered by date